

April 24, 2024

OTC Markets Group
330 Vessey Street - 12th Floor
New York, NY 10282

Re: Endonovo Therapeutics, Inc., SYMBOL: ENDV - Sufficiency of Adequate Current Information

Ladies and Gentlemen:

Please be advised that I am securities counsel to Endonovo Therapeutics, Inc., a Delaware corporation (the "Issuer"). I have been requested, as securities counsel to the Issuer, to render a sufficiency of adequate current information opinion (this "Opinion") in connection with the filing by the Issuer on April 24, 2024 of an Annual Report for the year ended December 31, 2023 including unaudited financial statements (the "2023 Annual") and all documents previously filed on the OTC Markets or with the Securities and Exchange Commission (collectively the "Historical Information"). (The 2023 Annual and the Historical Information are sometimes hereinafter referred to collectively as the "Filed Documents").

For the reasons set forth herein, it is my opinion that the Filed Documents, taken together: (i) constitutes adequate current public information concerning the shares of common stock of the Issuer (the "Securities") and the Issuer and is available within the meaning of Rule 144(c)(2) under the Securities Act; (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the shares of common stock of the Corporation (the "Securities"), under Rule 15c2-11 of the Exchange Act; (iii) complies as to form with the Pink OTC Markets Inc. Guidelines for Providing Adequate Current Information, which are located on the Internet at www.OTCMarkets.com; and (iv) has been posted in the OTC Markets Group News Service. Please be advised that OTC Markets Group ("OTCMG") is entitled to rely on this Opinion in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act.

In rendering the Opinion, I have reviewed such corporate records and other documents as I have deemed necessary regarding the filing of the Filed Documents. I have represented the Company for over a decade and have personally met with its sole director and CEO, Alan Collier, on many occasions and we have discussed the Company, in terms of both its history and its plans and prospects. In addition, I have made such investigations and have considered such questions of law as I deemed necessary and appropriate for the purposes of rendering this Opinion. In all such examinations, I have assumed the genuineness of all signatures, the authenticity of all documents submitted to me as originals, the conformity to original documents of all documents submitted to me as copies and the authenticity of all originals of such documents submitted as copies. Further, in all such examinations, I may have relied on information obtained from public officials, officers of the Issuer and other sources and represents that all such sources are reasonably believed to be reliable.

The person responsible for the preparation of the unaudited financial statements and notes thereto contained in the 2023 Annual was Alan Collier, CEO of the Company who was assisted by Ali Shan Aslam, an accounting consultant to the Issuer as required. Mr. Aslam is a chartered accountant. Mr. Collier, in his capacity as an officer of the Issuer has certified that the financial statements to present fairly, in all material respects, the financial position, results of operations and cash flows for the periods presented, in conformity with accounting principles generally accepted in the United States of America, consistently applied. In the opinion of management, all adjustments considered necessary for fair presentation have been included in the financial statements.

The Issuer's transfer agent (the "Transfer Agent") is Equity Stock Transfer, 237 W 37th St #602, New York, NY 10018 (tel) 212-575-5757. The Transfer Agent is registered with the Securities and Exchange Commission. I have

communicated with the Transfer Agent and viewed a recent shareholder statement to confirm the number of shares outstanding, the float and the existence of any large undisclosed shareholders.

The documents containing the information concerning the Issuer and the Securities that are publicly available as of the date of this letter are the Filed Documents as defined above.

I have personally reviewed the Filed Documents together with all exhibits and it is my legal opinion that such information taken together comport with all necessary requirements of Rule 144(c)(2) under Securities Act, and that to the best of my knowledge those documents taken together are accurate, up to date, and contain the most current information available on the Issuer, and that an interested investor would find current information therein which could help him objectively determine corporate and financially relevant information better enabling him to make an informed and educated and intelligent decision. I have discussed with management and received management's approval of this Opinion. Moreover, to the best of my knowledge, after inquiry of management of the Issuer, neither the Issuer nor its Board of Directors nor any 5% or greater shareholder is currently under investigation by any Federal or state regulatory authority for any violation of federal or state securities laws. Furthermore, after reasonable inquiry, I confirm the ownership information with respect to the Issuer's officers and directors and 5% beneficial owners set forth in the Filed Documents.

I am a resident of the State of New York and admitted to practice law in the State of New York. I have been retained by Issuer as its general securities counsel which includes being retained for the purpose of rendering this Opinion and related matters. My relationship as counsel to the Issuer is solely as a lawyer serving as securities counsel and in connection therewith I have been retained for the purpose of reviewing the current information provided by the Issuer. I have never been prohibited from practicing before the Securities and Exchange Commission. I do not own any securities of the Issuer. To my knowledge, I am not currently under investigation by any federal or state or foreign regulatory authority and I have never been the subject of any proceeding by the SEC, the U.S. Commodity Futures Trading Commission (CFTC), the Financial Industry Regulatory Authority (FINRA), or any other federal, state, or foreign regulatory agency. I am not now and have never been suspended or barred from practicing in any state or jurisdiction, and have never been charged in a civil or criminal case or been the subject of any investigation related thereto. I own 6,500,000 shares of the Issuer's common stock. This opinion is as to the laws of the States of Delaware and New York and the laws of the United States of America.

After careful review of the Filed Documents it is my opinion that the Issuer has never been a "shell company" as defined under Rule 405 under the Securities Act.

The opinions set forth herein are expressed as of the date hereof and remain valid so long as the document, instruments, records and certificates I have examined and relied upon, as noted above, are unchanged and the assumptions made, as noted above, are valid. While this Opinion is intended exclusively for use by OTC Markets Group, the same is hereby granted full and complete rights and permission without any future request to publish this Opinion on www.OTCMarkets.com for viewing by the public and regulatory agencies.

Very truly yours,



Frank J. Hariton